➡️Igalmi (dexmedetomidine) Sublingual Film

Company: BioXcel Therapeutics, Inc.
Date of Approval: April 5, 2022
Treatment for: Agitation

Igalmi (dexmedetomidine) is a sublingual film formulation of the approved alpha2-adrenergic receptor agonist dexmedetomidine indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

https://news.1rj.ru/str/ppdprogram

➡️Norliqva (amlodipine besylate) Oral Solution

Date of Approval: February 24, 2022
Company: CMP Pharma, Inc.
Treatment for: High Blood Pressure, Coronary Artery Disease, Angina

Norliqva (amlodipine besylate) is an oral solution formulation of the approved calcium channel blocker amlodipine for the treatment of hypertension and angina in patients with coronary artery disease.

https://news.1rj.ru/str/ppdprogram

➡️Releuko (filgrastim-ayow) Injection

Date of Approval: February 25, 2022
Company: Kashiv BioSciences, LLC
Treatment for: Neutropenia Associated with Chemotherapy, Neutropenia

Releuko (filgrastim-ayow) is a recombinant human granulocyte colony-stimulating factor biosimilar to Neupogen indicated for the treatment of neutropenia associated with chemotherapy and related conditions.

https://news.1rj.ru/str/ppdprogram

➡️Carvykti (ciltacabtagene autoleucel) Suspension for Intravenous Infusion

Date of Approval: February 28, 2022
Company: Janssen Pharmaceutical Companies
Treatment for: Multiple Myeloma

Carvykti (ciltacabtagene autoleucel) is a BCMA-directed CAR-T immunotherapy for the treatment of patients with relapsed or refractory multiple myeloma.

https://news.1rj.ru/str/ppdprogram

➡️Pyrukynd (mitapivat) Tablets

Date of Approval: February 17, 2022
Company: Agios Pharmaceuticals, Inc.
Treatment for: Pyruvate Kinase Deficiency

Pyrukynd (mitapivat) is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

https://news.1rj.ru/str/ppdprogram

➡️Vonjo (pacritinib) Capsules

Date of Approval: February 28, 2022
Company: CTI BioPharma Corp.
Treatment for: Myelofibrosis

Vonjo (pacritinib) is a JAK2/FLT3 multikinase inhibitor for the treatment of myelofibrosis patients with severe thrombocytopenia.

https://news.1rj.ru/str/ppdprogram

➡️Spikevax (Moderna COVID-19 Vaccine) (COVID-19 Vaccine, mRNA) Injection - formerly mRNA-1273

Date of Approval: January 31, 2022
Company: Moderna, Inc.
Treatment for: Prevention of COVID-19

Spikevax (COVID-19 Vaccine, mRNA) is an mRNA vaccine indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

https://news.1rj.ru/str/ppdprogram

➡️Ztalmy (ganaxolone) Oral Suspension

Date of Approval: March 18, 2022
Company: Marinus Pharmaceuticals, Inc.
Treatment for: CDKL5 Deficiency Disorder

Ztalmy (ganaxolone) is neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)

https://news.1rj.ru/str/ppdprogram

➡️Opdualag (nivolumab and relatlimab-rmbw) Injection

Date of Approval: March 18, 2022
Company: Bristol Myers Squibb
Treatment for: Melanoma

Opdualag (nivolumab and relatlimab-rmbw) is programmed death receptor-1 (PD-1) blocking antibody and lymphocyte activation gene-3 (LAG-3) blocking antibody combination indicated for the treatment of unresectable or metastatic melanoma.

https://news.1rj.ru/str/ppdprogram

➡️Pluvicto (lutetium lu 177 vipivotide tetraxetan) Injection

Date of Approval: March 23, 2022
Company: Novartis
Treatment for: Prostate Cancer

Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent indicated for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

https://news.1rj.ru/str/ppdprogram

➡️Hyftor (sirolimus) Topical Gel

Date of Approval: March 22, 2022
Company: Nobelpharma America, LLC
Treatment for: Facial Angiofibroma Associated with Tuberous Sclerosis

Hyftor (sirolimus topical gel) is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older.

https://news.1rj.ru/str/ppdprogram

➡️Nasonex 24HR Allergy (mometasone furoate monohydrate) Nasal Spray

Date of Approval: March 17, 2022
Company: Perrigo Company plc
Treatment for: Allergic Rhinitis

Nasonex 24HR Allergy (mometasone furoate monohydrate) is a corticosteroid nasal spray available over-the-counter for the temporary relief of the symptoms of hayfever or other upper respiratory allergies.

https://news.1rj.ru/str/ppdprogram

➡️Zegalogue (dasiglucagon) Injection

Date of Approval: March 22, 2021
Company: Zealand Pharma A/S
Treatment for: Hypoglycemia

Zegalogue (dasiglucagon) is a glucagon analog antihypoglycemic agent for the treatment of severe hypoglycemia in diabetes patients aged 6 years and older.

https://news.1rj.ru/str/ppdprogram

➡️Lybalvi (olanzapine and samidorphan) Tablets

Date of Approval: May 28, 2021
Company: Alkermes plc
Treatment for: Schizophrenia, Bipolar Disorder

Lybalvi (olanzapine and samidorphan) is a combination of an established antipsychotic agent (olanzapine) and a novel μ-opioid receptor antagonist (samidorphan) for the treatment of schizophrenia and bipolar I disorder.

https://news.1rj.ru/str/ppdprogram

➡️Astepro Allergy (azelastine) Nasal Spray

Date of Approval: June 17, 2021
Company: Bayer HealthCare LLC
Treatment for: Allergic Rhinitis

Astepro Allergy (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis.

https://news.1rj.ru/str/ppdprogram

➡️Wegovy (semaglutide) Injection

Date of Approval: June 4, 2021
Company: Novo Nordisk
Treatment for: Obesity

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are overweight (BMI ≥27 kg/m2) or obese (BMI ≥30 kg/m2).

https://news.1rj.ru/str/ppdprogram

➡️Soaanz (torsemide) Tablets

Date of Approval: June 14, 2021
Company: Sarfez Pharmaceuticals
Treatment for: Edema

Soaanz (torsemide) is a loop diuretic indicated for the treatment of edema associated with heart failure or renal disease in adults.

https://news.1rj.ru/str/ppdprogram

➡️Verkazia (cyclosporine) Ophthalmic Emulsion

Date of Approval: June 23, 2021
Company: Santen Inc.
Treatment for: Vernal Keratoconjunctivitis

Verkazia (cyclosporine) is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.

https://news.1rj.ru/str/ppdprogram

➡️Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Injection

Date of Approval: June 30, 2021
Company: Jazz Pharmaceuticals plc
Treatment for: Acute Lymphoblastic Leukemia

Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).

https://news.1rj.ru/str/ppdprogram

➡️Kerendia (finerenone) Tablets

Date of Approval: July 9, 2021
Company: Bayer
Treatment for: Chronic Kidney Disease Associated with Type 2 Diabetes

Kerendia (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist (MRA) for the treatment of patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

https://news.1rj.ru/str/ppdprogram

➡️(fexinidazole) Tablets

Date of Approval: July 16, 2021
Company: Drugs for Neglected Diseases Initiative
Treatment for: Trypanosomiasis

Fexinidazole is a nitroimidazole antibacterial indicated for the treatment of human African trypanosomiasis (African sleeping sickness) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg.

https://news.1rj.ru/str/ppdprogram